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in the United KingdomTo the Editor:
X-linked chronic granulomatous disease (XL-CGD) due to a
defect in the nicotinamide adenine dinucleotide phosphate-oxi-
dase (NADPH) oxidase complex subunit gp91phox encoded by
CYBB impairs neutrophil respiratory oxidative burst (NROB).
In the United Kingdom, the incidence is approximately 1 in
125,000 of which 70% are X-linked.1 Patients experience
recurrent, severe bacterial and fungal infection2 as well as
inflammatory and autoimmune complications,3 which cause
significant morbidity and mortality.
XL-CGD female carriers have a dual phagocyte population due
to lyonization, with 20% to 80% functioning phagocytes.4
Reports of XL-CGD female carriers with discoid lupus
erythematosus, photosensitivity,4 gastrointestinal symptoms,
chorioretinitis, and autoimmune phenomena are published.4 We
performed a detailed health survey of XL-CGD carriers identified
from families known to the UK CGD registry1 and via the CGD
Society. Carriers were confirmed by a dual phagocytic cell
population measured by the nitroblue tetrazolium test or
dihydrorhodomine flow cytometric assay. The presence of
gastrointestinal symptoms and symptoms related to systemic
lupus erythematosus (SLE) defined by American Rheumatology
Association (ARA) diagnostic criteria5 were specifically sought.
An estimate of neutrophil function was measured at the recruiting
center using dihydrorhodomine, at enrollment. Available
previous results were recorded. Antinuclear, antigastric parietal
cell, antimitochondrial, and anti–smooth muscle autoantibodies
were measured by standard routine methodologies.
Of 94 XL-CGD carrier families identified from the UK registry,
81 XL-CGD carriers, from 62 families, were recruited; completedata were available for 61 (see Table E1 in this article’s Online
Repository at www.jacionline.org).
Median NROB at enrollment was 47% (range, 7% to 94%),
compared with a historical median of 52%, performed at any time
before study commencement. Most subjects had an NROB of
20% to 60%: there was no significant correlation with carrier age.
Skin symptoms were reported by 63 (79%) subjects, most
frequently photosensitivity. Other symptoms included a malar,
lupus-like rash, and eczema (see Table E2 in this article’s Online
Repository at www.jacionline.org). Adult acne was present in 8
(10%), reminiscent of CGD folliculitis. There was no significant
difference in median NROB in affected versus nonaffected
subjects. Skin abscesses were reported in 14 (17%), in whom
the NROB was significantly lower than in nonaffected carriers
(P 5 .0088).
Gastrointestinal symptoms were reported by 40 carriers, most
frequently abdominal pain and diarrhea. Most did not have a
defined diagnosis: 3 had inflammatory bowel disease.
Fifteen were investigated for symptoms (see Table E3 in this
article’s Online Repository at www.jacionline.org). Four had
undergone appendicectomy, but histologic results were not avail-
able. Thirteen were investigated; histologic features of Crohn dis-
ease were reported in 2 and colitis was reported in 1—similar to
those reported in CGD colitis. The NROBwas lower in symptom-
atic carriers (abdominal pain, diarrhea, rectal bleeding), but did
not reach statistical significance (P 5 .08). The NROB was
significantly lower in subjects affected by diarrhea (P 5 .009)
(Table I). The presence of colitis in an index case correlated
with symptoms in the related carriers (P 5 .03).
Features of SLE (see Table E4 in this article’s Online
Repository at www.jacionline.org) were compared with a
cohort of European patients with SLE.6 Photosensitivity, oral
ulcers, Raynaud phenomenon, and arthritis occurred more
frequently in carriers than in the reference cohort. There was no
significant difference in the ratio of normal neutrophil
function in symptomatic compared with nonsymptomatic
subjects (see Table E5 in this article’s Online Repository at
www.jacionline.org).
Fifty-seven percent of carriers (n 5 45) met 3 or more ARA
SLE criteria, and more than 25% met 4 or more, consistent with
SLE (Table E5), but only 18% had been diagnosed with a
lupus-like disorder, most of whom were not labeled as having
SLE. There was no significant difference in NROB when
considering the number of ARA criteria met (P 5 .6 by 1-way
ANOVA). A positive antinuclear antibody was infrequently
encountered as one of the ARA SLE criterion. Clinical
manifestations of SLE that were unusual were nephropathy,
serositis, and neurological involvement.
Those in whom joint symptoms were elicited reported episodic
inflammation, pain, and redness, associated with extreme fatigue,
suggesting an inflammatory rather than degenerative pattern.
More carriers who reported joint symptoms were autoantibody
positive when tested (19% vs 14%).
Autoantibody results were available for 51 participants:
42 had a negative panel, 12 had 1, and 2 had 2 or more
positive autoantibodies. The antinuclear antibody (ANA) was
positive (>1:40) in 8 carriers, with 4 demonstrating positive
antigastric parietal cell antibody and 1 each demonstrating
antimitochondrial and anti–smooth muscle autoantibodies,
respectively. There was no clear correlation with symptoms
(Tables I and E5).
TABLE I. Percentage of normal neutrophil function and autoantibody positivity in XL-CGD carriers with and without symptoms
Symptom No. affected (%)
Mean NROB
in the
affected
group
Mean NROB
in the
unaffected
group
Paired
t test
P value
Autoantibody
positivity in
the affected
group (%)
Autoantibody
positivity in the
unaffected group
(% positive)
GI symptoms
Any GI symptom 40 (50) 44 52 .08 16
Abdominal pain 25 (31) 40 52 .05 10
Diarrhea 24 (30) 37 54 .009 10
Rectal bleeding 17 (21) 44 50 .16 4
Gastrointestinal diagnoses
Inflammatory bowel disease/CGD colitis 3 (4) 16 NA 0
Irritable bowel syndrome 8 (9.8) 44 40
Other 2 (2.5) 32 0
No formal GI diagnosis 56 (69) 48 10
Photosensitivity 57 (74) 46 49 .3 25 5
Oral ulcers 57 (74) 46 54 .13 17 24
Raynaud phenomenon 27 (35) 49 46 .3 13 14
Joint symptoms 48 (62) 47 47 .46 19 14
Fatigue 37 (51) 43 51 .08 23 30
GI, Gastrointestinal; NA, not applicable/available.
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ARA criteria for SLE compared with 43% in those with 4 or more
(Table E5). Thirteen received hydroxychloroquine treatment.
We report wide-ranging inflammatory and autoimmune symp-
toms in XL-CGD carriers, many of which overlap with clinical
presentations of patients with CGD. Themost striking findingwas
that 26% of carriers met 4 or more of the ARA SLE diagnostic
criteria and only 18% had been diagnosed with a lupus-like
disorder. This has not been previously described as such a
common problem in this population. Anecdotally, carriers with
SLE-like symptoms were told that they did not have SLE because
autoantibodies were negative. The phenotype is more extensive
than previously highlighted features of discoid lupus, and the
pattern is different to the reference Euro-lupus cohort, who had
more organ involvement. Previous reports have referred to a
‘‘lupus-like’’ disease in XL-CGD carriers due to the lack of
positive ‘‘lupus autoantibodies.’’4,7 However, symptom pattern
may suggest a different process, forming part of the spectrum
of disease of SLE, rather than ‘‘classical’’ SLE.8 Failure to
associate symptoms with CGD, or with an SLE variant, has led
to inadequate treatment and ongoing symptoms.
Reports of XL-CGD carriers with extreme X-inactivation
suffering from inflammatory bowel disease have been published.9
We demonstrate that bowel symptoms are more prevalent than
previously recognized although few were investigated. There
was a significant correlation between carriers and index
case experiencing gastrointestinal symptoms, suggesting an
association of symptoms with a shared environment.
Our study suggests that symptomatic XL-CGD carriers warrant
further investigation and treatment. All known UK families were
approached for this study, thus limiting bias toward only
symptomatic carriers. Identifying carriers most at risk of
developing symptoms was not possible, because there was no
clear correlation with degree of neutrophil function or with
detection of autoantibodies by immunofluorescence, although the
association of bowel symptoms within families is intriguing.
We recommend that symptomatic XL-CGD carriers be
managed proactively, and reviewed by a suitably qualified
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attenuates anaphylactic reactions
in miceTo the Editor:
Anaphylaxis is a severe and life-threatening allergic reaction.
As of the last decade, 0.05% to 2% of the general population
worldwide experienced an anaphylactic reaction during their
lifetime, and approximately 2% of these subjects died as a result
of the reaction.1
Clinical and experimental studies have shown that vascular
hyperpermeability is a hallmark of anaphylaxis.2,3 Activatedmast
cells release vasoactive mediators, such as histamine and platelet-
activating factor, which induce the initial anaphylactic response
of vascular hyperpermeability by causing vasodilation, endothe-
lial barrier disruption, or both. Systemic vascular hyperperme-
ability and plasma leakage into local tissues lead to systemic
reactions, including increased hematocrit levels and hypotension.
Prostaglandin D2 (PGD2) is produced by the activity of COX
and hematopoietic PGD synthase (H-PGDS). Because a previous
study demonstrated that mast cells strongly express H-PGDS and
produce PGD2 on a large scale,
4 we hypothesized that mast cell–
derived PGD2 makes some pathophysiologic contribution to
anaphylaxis, although the exact nature of this contribution is
unknown.
We first examined anaphylactic vascular hyperpermeability
under conditions in which PGD2 was present or absent. Intrave-
nous injection of the antigen dinitrophenyl (DNP) into the
DNP-IgE–sensitized mouse ear induced the extravasation of
intravenously injected dye in wild-type (WT) mice (Fig 1, A
and B). Intradermal injection of compound 48/80 (C48/80) also
induced extravasation in WT mice (Fig 1, C and D). A higher de-
gree of dye extravasation was observed in H-PGDS–deficient
(Hpgds2/2) mice than in WT mice (Fig 1, A and B). Hpgds2/2
mice also exhibited a stronger increase in hematocrit levels,
more severe hypotension, and deeper and longer hypothermia
compared with WT mice in response to systemic mast cell–acti-
vating stimulation (Fig 1, E and F, and see Fig E1 in this article’s
Online Repository at www.jacionline.org). In contrast, overex-
pression of H-PGDS (HTG) attenuated the C48/80-induced hypo-
thermia (Fig 1, G). These results suggest that H-PGDS–derived
PGD2 inhibits vascular hyperpermeability and systemic re-
sponses in patients with anaphylaxis.
Mast cell–induced anaphylactic responses are largely attribut-
able to histamine release and subsequent nitric oxide (NO)
production from endothelial cells.5,6 C48/80 stimulation pro-
duced comparable increases in plasma levels of histamine in the
2 lines of mice (see Fig E2, A, in this article’s Online Repository
at www.jacionline.org), and pretreatment with the histamine H1receptor blocker diphenhydramine abolished the C48/80-
induced hyperpermeability and hypothermia (see Fig E2, B-D).
H-PGDS deficiency did not influence the sensitivities to hista-
mine (see Fig E2, E-G). Lack of the endothelial NO synthase
gene also abolished the C48/80-induced anaphylactic responses
(see Fig E3, A and B, in this article’s Online Repository at
www.jacionline.org). Moreover, pretreatment with the NO syn-
thase inhibitor NG-nitro-L-arginine methyl ester hydrochloride
(L-NAME) led to a nonsignificant inhibition of dye extravasation
and hypothermia in WT mice, whereas it significantly inhibited
the responses in Hpgds2/2 mice (see Fig E3, C-E), suggesting
increased NO production in the PGD2-absent condition.
Immunostaining results indicated that mast cells localized with
a-smooth muscle actin (a-SMA)–positive and platelet endothelial
cell adhesion molecule (PECAM) 1–positive vessels and that their
numbers were comparable between WT and Hpgds2/2 mice (see
Fig E4, A and B, in this article’s Online Repository at www.
jacionline.org). The perivascular mast cells strongly expressed
H-PGDS in the ears of WT but not Hpgds2/2 mice (Fig 1, H).
We then generated mast cell–specific H-PGDS–deficient mice
(Mcpt5CreHpgdsfl/fl) by crossing mast cell protease 5 (MCPT5)-
Cre transgenic mice and H-PGDS floxed mice (see Fig E4, C-E
and Fig E7 in this article’s Online Repository at www.jacionline.
org). Compared with the control mice (Hpgdsfl/fl), Mcpt5Cre
Hpgdsfl/fl mice exhibited enhanced vascular hyperpermeability
without PGD2 production in response to C48/80 (Fig 1, I-K). On
the other hand, Mcpt5CreHpgdsfl/fl mice exhibited a slight but
nonsignificant increase in C48/80-induced hypotension and hypo-
thermia compared with the Hpgdsfl/fl mice (Fig 1, L andM).
There are 2 major types of mast cells: connective tissue–type
mast cells (CTMCs) and mucosal-type mast cells (MMCs).
CTMCs typically reside in the skin and the peritoneal cavity,
whereas MMCs are predominant in the mucosal layer of the lung
and intestine. Because the protease MCPT5 is mainly expressed
in CTMCs but is rarely expressed in MMCs, Mcpt5CreHpgdsfl/fl
mice lack H-PGDS in CTMCs. MCPT5CreiDTR1 mice, in
which CTMCs are selectively depleted by diphtheria toxin,
exhibit a strong reduction of anaphylactic hypothermia while
still exhibiting a small response because of residual MMCs.7
MMC-derived PGD2 can also be involved in anaphylaxis
suppression.8
We next examined the contribution of 2 distinct PGD2 recep-
tors to the attenuation of anaphylaxis. Systemic DP deficiency
(Dp2/2, see Fig E7) but not CRTH2 receptor deficiency
(Crth22/2) significantly increased dye extravasation compared
with that seen in WT mice (Fig 2, A and B). Administration of
PGD2 or a DP agonist inhibited the C48/80-induced vascular hy-
perpermeability (Fig 2, C and D, and see Fig E5 in this article’s
Online Repository at www.jacionline.org). There is another
endogenous DP ligand, PGD1, which has much lower affinity
than PGD2. However, the high dose of PGD1 (1mg) did not inhibit
anaphylactic hyperpermeability (see Fig E5). The DP agonist also
attenuated hypothermia in both mouse lines (Fig 2, E). Although
it is reported that DP activation induces vasodilation in isolated
vessels of the human lung,9 it did not influence the blood pressure
of mice in this regimen (see Fig E6 in this article’s Online Repos-
itory at www.jacionline.org). Anaphylactic vascular hyperperme-
ability depends on endothelial Gq/G11/intracellular calcium
([Ca21]i)–induced NO production.
3,6 Activation of the Gs-
coupled DP receptor increases intracellular cyclic AMP, which
activates protein kinase A and decreases [Ca21]i levels. Results
TABLE E1. Baseline demographic characteristics of XL-CGD
carriers
No. of carriers 81
% Alive 97.5
Median age (y) (range) 42.5 (3-77)
Ethnicity (% white British) 96
Median age of index case (y) (range) 12 (1-43)
Relationship to index case (% mothers) 69
Exclusions
Deceased index case 4
Non-UK resident 11
New mutation in index case 5
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TABLE E2. Skin and infective manifestations in XL-CGD carriers
Manifestation No. of carriers (%)
Photosensitivity 56 (74)
DLE/malar rash 30 (40)
Eczema 11 (14)
Psoriasis 3 (4)
Adult acne 8 (10)
Erythema multiforme 2 (3)
Dermatitis 5 (7)
Allergic/hives 5 (7)
Rosacea 5 (7)
Malignancy 1 (1)
Any significant infection 19 (23.5)
Fungal infection 1 (1.2)
Pneumonia 4 (4.9)
Meningitis 2 (2.5)
Recurrent skin abscesses 14 (17)
Sinus infection 2 (3)
Lymphadenitis 4 (5)
Alopecia 6 (8)
DLE, Discoid lupus erythematosus.
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TABLE E3. Gastrointestinal investigations in XL-CGD carriers
Carrier Investigation Investigation finding
3 Colonoscopy
Endoscopy
Colitis consistent with CGD colitis
Hiatus hernia
4 Colonoscopy Minor, nonspecific inflammation (reported as not significant)
11 Labeled white cell
Small-bowel follow-through endoscopy
USS
Normal
Normal
Hiatus hernia and gastritis
Normal
13 Gastroscopy Normal duodenal biopsy
Telangiectasia
Normal GI tract
20 USS Normal
21 Colonoscopy Crohn disease
34 Body scan Diverticular disease
36 Colonoscopy No significant abnormality
39 Colonoscopy Crohn disease
Patchy inflammatory abscesses with cryptitis and crypt abscesses. No convincing
granulomas. Consistent with mild/moderate chronic inflammation
Sigmoidoscopy Mild nonspecific inflammation
Indeterminate colitis
Colonoscopy and endoscopy Patchy inflammatory changes. Acute inflammation with cryptitis and crypt abscesses.
Mild chronic inflammation in left colon. No convincing granulomas.
The appearances are of patchy mild and moderate active chronic inflammation,
in keeping with clinical history of Crohn disease
42 Sigmoidoscopy Normal
53 Endoscopy Esophagitis (early Barrets)
GI, Gastrointestinal; USS, ultrasound scan.
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TABLE E4. SLE symptoms in XL-CGD carrier cohort compared
with published data of European SLE cohort*
Problem
Euro-Lupus cohort,
n (%)
CGD carrier
cohort, n (%)
P
value
Malar rash 311 (31.1) 30 (39) .07
Photosensitivity 229 (22.9) 57 (74) <.01
Oral ulcers 125 (12.5) 57 (76) <.01
Raynaud phenomenon 163 (16.3) 27 (35) <.01
Arthritis 481 (48.1) 48 (62) .01
Serositis 160 (16.0) 3 (3.8) .003
Nephropathy 279 (27.9) 3 (3.8) <.001
Neurological involvement 194 (19.4) 3 (3.8) <.005
Death 68 (6.8) 2 (3) <.0001
Boldface type signifies more significant in the CGD carrier group, italic type signifies
more significant in the Euro SLE group.
*O’Neill S, Cervera R. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol
2010;24:841-55.
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TABLE E5. The number of ARA criteria for the diagnosis of SLE
met, percentage with positive autoantibodies positivity, and
mean percentage of normal neutrophil function in XL-CGD
carriers
No. of ARA
criteria met
No. of XL-CGD
carriers
Autoantibody
positivity
(%) (% carriers
ANA positive)
NROB
(mean)
0 10 0 (0) 62
1 9 11 (0) 54
2 17 12 (12) 43
3 24 17 (4) 47
41 21 33 (24) 43
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TABLE E6. Autoimmune features in XL-CGD carriers with NROB in affected and unaffected groups and autoantibody positivity
Symptom No. affected (%)
Mean NROB
in the affected
group
Mean NROB
in the unaffected
group
Paired t test
P value
Autoantibody positivity
(% positive in affected)
Autoantibody positivity
in the unaffected
group (% positive)
Photosensitivity 57 (74) 46 49 .3 25 5
Oral ulcers 57 (74) 46 54 .13 17 24
Raynaud phenomenon 27 (35) 49 46 .3 13 14
Joint symptoms 48 (62) 47 47 .46 19 14
Fatigue 37 (51) 43 51 .08 23 30
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